Stock Events

Stock Events

Search...

Biosenic

€0

2

+€0+0% Today

Statistics

Day High

0

Day Low

0

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

2.31M

P/E Ratio

0

Dividend Yield

-

Dividend

-

Earnings

20MayExpected

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

0

0.33

0.67

1

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BT1.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Biosenic's offerings.

Thermo Fisher Scientific

Thermo Fisher Scientific offers a broad range of biotechnology products, including genomics and proteomics tools, which overlap with Biosenic's market.

Qiagen is known for sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the diagnostics and research market.

Bio-Rad Laboratories

Bio-Rad Laboratories manufactures and supplies products and systems used for gene expression, protein purification, and analysis, which are areas Biosenic may also operate in.

Pacific Biosciences of California

Pacific Biosciences offers long-read sequencing technologies, which can be seen as complementary or competitive to Biosenic's offerings depending on their focus in genomics.

Agenus is involved in immuno-oncology, a field that may overlap with Biosenic's work if they are involved in developing therapies or diagnostics based on genetic information.

Guardant Health

Guardant Health focuses on liquid biopsies and cancer diagnostics through genomic sequencing, competing in the precision medicine space.

Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, which could be a competitor if Biosenic is involved in therapeutic applications of genomics.

CRISPR Therapeutics

CRISPR Therapeutics is focused on developing gene-based medicines, potentially competing with Biosenic if they are involved in therapeutic genomics.

About

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

Show more...

CEO

Prof. François Rieger

Country

BE

ISIN

BE0974280126

WKN

000A14NHV

Listings